Arvee Laboratories

₹187.3 0 | 0%

WEBSITE BSE:0 NSE : 17 May, 00:00

Market Cap ₹206 Cr.

Stock P/E 196.4

P/B 7.1

Current Price ₹187.3

Book Value ₹ 26.4

Face Value 10

52W High ₹315

Dividend Yield 0%

52W Low ₹ 98.1

Edit Ratio

Arvee Laboratories Research see more...

Overview Inc. Year: 2012Industry: Chemicals

Arvee Laboratories India Limited is a chemical manufacturing company that was founded in 2012 by Mr. Rajesh Patel and Mr. Vipul Patel, who envisioned an eco-friendly organization dedicated to providing good quality innovative products at very competitive prices. Company produces polymer modifiers, contrast media intermediates along with drug intermediates. It oversees operations from its plant in Navagam, Gujarat, which has a capacity of 6000 MT per annum. Their vision is to become a front-runner in the chemical industry by offering the best and innovative quality chemical products. The company has received several awards and recognitions, such as the Best SME Award from the Gujarat Chamber of Commerce and Industry in 2021, the Green Chemistry Award from the Indian Chemical Council in 2020, and the Innovation Award from the Federation of Indian Chambers of Commerce and Industry in 2019.

Arvee Laboratories Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Arvee Laboratories Quarterly Results

#(Fig in Cr.)	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Net Sales	8	13	18	23	16	13	8	9	8	6
Other Income	0	0	0	0	0	0	0	0	0	0
Total Income	8	13	18	23	16	13	8	9	8	6
Total Expenditure	7	11	16	19	15	11	7	8	7	5
Operating Profit	1	2	2	3	2	1	1	1	1	1
Interest	0	0	0	0	0	0	0	0	0	0
Depreciation	0	1	1	0	0	0	0	0	0	0
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	1	1	2	3	1	1	1	0	0	1
Provision for Tax	-0	0	0	1	0	1	0	0	0	0
Profit After Tax	1	1	1	2	1	0	0	0	0	0
Adjustments	-0	0	0	-0	0	-0	0	0	0	0
Profit After Adjustments	1	1	1	2	1	0	0	0	0	0
Adjusted Earnings Per Share	1.1	0.7	1	1.9	0.8	0	0.4	0.2	0.2	0.1

Arvee Laboratories Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	3	12	13	27	34	48	55	45	47	40	61	31
Other Income	0	0	0	0	1	0	0	0	1	1	1	0
Total Income	4	12	13	27	35	48	55	46	48	41	63	31
Total Expenditure	3	10	11	22	29	41	49	39	41	35	54	27
Operating Profit	0	2	2	5	6	7	7	6	7	6	9	4
Interest	0	2	2	3	3	3	2	1	1	0	0	0
Depreciation	0	0	1	1	2	2	2	2	2	2	2	0
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	0	0	-1	1	1	2	3	3	4	3	6	2
Provision for Tax	0	0	1	0	-1	1	0	1	1	1	2	0
Profit After Tax	0	0	-2	0	2	1	2	2	3	3	4	0
Adjustments	0	0	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	0	0	-2	0	2	1	2	2	3	3	4	0
Adjusted Earnings Per Share	0	0	0	0	0	1	2.1	2.1	2.4	2.3	3.7	0.9

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	53%	11%	5%	35%
Operating Profit CAGR	50%	14%	5%	0%
PAT CAGR	33%	26%	32%	0%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	72%	2%	43%	NA%
ROE Average	16%	14%	14%	10%
ROCE Average	23%	18%	17%	14%

Arvee Laboratories Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	0	3	1	3	4	14	16	19	21	24	28
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	7	8	15	17	17	8	3	2	1	1	1
Other Non-Current Liabilities	0	0	1	1	0	1	1	0	0	0	1
Total Current Liabilities	2	6	9	14	15	21	17	12	18	14	9
Total Liabilities	9	17	26	35	36	44	37	34	41	39	39
Fixed Assets	0	2	9	13	17	15	13	13	14	14	13
Other Non-Current Assets	3	7	5	4	0	2	3	2	2	1	4
Total Current Assets	6	8	12	18	19	27	21	18	26	24	22
Total Assets	9	17	26	35	36	44	37	34	41	39	39

Arvee Laboratories Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	0	0	0	1	1	1	2	4	1	7	1
Cash Flow from Operating Activities	4	-0	9	6	4	6	9	10	2	4	3
Cash Flow from Investing Activities	-3	-6	-6	-5	-1	-1	-3	-3	-1	0	-1
Cash Flow from Financing Activities	-1	7	-2	-1	-3	-4	-5	-10	5	-6	-2
Net Cash Inflow / Outflow	0	0	1	0	-0	1	2	-3	6	-2	-1
Closing Cash & Cash Equivalent	0	0	1	1	1	2	4	1	7	5	1

Arvee Laboratories Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	0	0	0	0	0	0.99	2.05	2.09	2.43	2.34	3.74
CEPS(Rs)	4.99	0.41	-1.54	2.07	4.47	2.94	4.19	4.16	4.61	4.44	5.63
DPS(Rs)	0	0	0	0	0	0	0	0	0	0	0
Book NAV/Share(Rs)	0	0	0	0	0	12.66	14.77	16.91	19.39	21.72	25.46
Core EBITDA Margin(%)	5.09	15.35	16.12	17.52	16.3	15.01	11.25	13.26	12.75	13.95	11.87
EBIT Margin(%)	8.27	13.76	11.16	13.45	12.6	10.98	7.61	8.98	8.9	9.47	10.68
Pre Tax Margin(%)	1.54	0.2	-7.76	2	2.5	4.01	4.63	6.8	7.69	8.55	10.05
PAT Margin (%)	1.25	0.16	-12.7	0.7	4.51	2.28	4.12	5.06	5.65	6.38	6.71
Cash Profit Margin (%)	1.45	2.06	-7.1	6.24	10.52	6.79	8.4	10.1	10.73	12.14	10.1
ROA(%)	0.48	0.14	-7.58	0.61	4.38	2.73	5.57	6.5	7.17	6.46	10.65
ROE(%)	46.24	1.19	-73.58	9.24	45.41	12.01	14.97	13.17	13.38	11.36	15.84
ROCE(%)	3.83	13.64	7.51	14.39	15.19	17.69	14.1	15.79	15.99	13.33	23.35
Receivable days	143.48	66.92	64.11	52.09	75.75	90.52	77.78	57.98	55.46	90.55	72.55
Inventory Days	61.42	54.41	130.98	91.43	70.46	54.94	42.44	44.51	53.54	59.55	30.63
Payable days	175.17	56.82	92.12	96.87	99.13	110.65	85.09	100.36	121.18	157.69	82.15
PER(x)	0	0	0	0	0	30.81	15.34	11.26	22.8	48.68	23.54
Price/Book(x)	0	0	0	0	0	2.41	2.13	1.39	2.86	5.23	3.46
Dividend Yield(%)	0	0	0	0	0	0	0	0	0	0	0
EV/Net Sales(x)	2.15	1.38	1.77	1.05	0.82	1	0.8	0.63	1.34	3.07	1.58
EV/Core EBITDA(x)	25.34	8.79	10.57	5.52	4.38	6.45	6.73	4.52	9.56	20.16	11.25
Net Sales Growth(%)	0	242.67	9.92	106.8	28.35	38.8	14.91	-17.27	4.31	-14.88	52.12
EBIT Growth(%)	0	470.56	-10.84	149.26	20.23	20.88	-20.34	-2.38	3.42	-9.45	71.58
PAT Growth(%)	0	-56.28	-8860.64	111.38	728.04	-29.81	107.77	1.6	16.46	-3.87	60.04
EPS Growth(%)	0	0	0	0	0	-48.41	107.77	1.6	16.46	-3.86	60.04
Debt/Equity(x)	78.97	4.35	14.69	9.59	5.96	1.16	0.79	0.21	0.42	0.13	0.04
Current Ratio(x)	3.68	1.24	1.33	1.24	1.26	1.28	1.29	1.43	1.4	1.75	2.44
Quick Ratio(x)	3.3	0.78	0.6	0.75	0.84	0.9	1.01	0.91	0.99	1.33	1.92
Interest Cover(x)	1.23	1.01	0.59	1.17	1.25	1.58	2.56	4.13	7.32	10.31	16.89
Total Debt/Mcap(x)	0	0	0	0	0	0.48	0.37	0.15	0.15	0.02	0.01

Arvee Laboratories Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	73.5	73.5	73.5	73.5	73.5	73.5	73.5	73.5	73.5	73.5
FII	0	0	0	0	0	0	0	0	0	0
DII	0	0	0	0	0	0	0	0	0	0
Public	26.5	26.5	26.5	26.5	26.5	26.5	26.5	26.5	26.5	26.5
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81
FII	0	0	0	0	0	0	0	0	0	0
DII	0	0	0	0	0	0	0	0	0	0
Public	0.29	0.29	0.29	0.29	0.29	0.29	0.29	0.29	0.29	0.29
Others	0	0	0	0	0	0	0	0	0	0
Total	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1

Pros

Company has delivered good profit growth of 31% CAGR over last 5 years
Debtor days have improved from 157.69 to 82.15days.
Company is almost debt free.

Cons

Company has a low return on equity of 14% over the last 3 years.
Stock is trading at 7.1 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.